June 3, 2024
Prof-001 (Candiplus®) - Phase 2b-3 completed
The excellent efficacy of Candiplus® in chronic recurrent fungal infections was demonstrated in phase 2b-3. Both the primary cure rate and the relapse rate show a significant improvement compared to the approved therapies.
PROFEM - Working for Women's Health
MISSION
CREATIVITY plus KNOWLEDGE
With this combination, we are taking medicine for women to a new level!
PROFEM solves therapeutic problems through systemic treatment concepts. Based on the latest pharmacological findings, treatment successes are made possible by combining proven medicinal substances in highly efficient forms of application where there was previously no cure.
# BREAK THE TABOO
For a large number of diseases that exclusively or primarily affect women, there are still no adequate treatment options. This is probably because no one talks about these diseases, they don't even know they exist! Both the number of people affected and the extent of suffering are underestimated. Our goal is to change this untenable state of affairs, through our commitment to research, but also through communication!
ACTIVITIES
Chronic infections of the bladder and lower genital tract are diseases affecting hundreds of millions of women worldwide. The formation and persistence of biofilms very often determine the disease process in such diseases. To date, the treatment of biofilm-associated diseases remains a largely unsolved medical problem. With the Candiplus® lead project, ProFem is introducing an innovative therapy concept for the treatment of such infections.
AWARDS
"Best project"
- Fempower 2012
"One of the 3 best business concepts".
- Best of Biotech 2010
SUPPORTED BY:
